Antacids and their role in treatment of digestive diseases in pregnant women
PDF (Русский)
PDF (Українська)

Keywords

antacids, acid-dependent diseases, gastroesophageal reflux disease, pregnancy.

How to Cite

Plotnikova, E. Y., & Vologzhanina, L. G. (2020). Antacids and their role in treatment of digestive diseases in pregnant women. Herald of Pancreatic Club, 47(2), 82-88. https://doi.org/10.33149/vkp.2020.02.10

Abstract views: 63
PDF Downloads: 18 PDF Downloads: 0

Abstract

Antacids are drugs that can neutralize or buffer the hydrochloric acid of the stomach without affecting its production. History of the clinical use of antacids dates back several centuries. The article discusses the advantages and disadvantages of modern antacids, provides a classification of drugs of this group, considers the mechanisms of their action, explains the term “acid-neutralizing activity”, lists indications for the use of antacids and possible adverse effects of antacid therapy. The results of various foreign and domestic studies on the use of acid-suppressive drugs, including antacids, are presented.

Currently, antacids continue to be used for the symptomatic treatment of certain acid-dependent diseases, including gastroesophageal reflux disease (GERD). Due to a number of physiological reasons, GERD often worries pregnant women, most often in the third trimester of pregnancy. The choice of acid-suppressing agents in pregnant women is extremely limited, because the possibility of prescribing any drugs in this category of patients is determined by the safety of the drug, its tolerability, and the absence of teratogenic effects. Features of the mechanism of action of antacids, their favorable pharmacological properties determine the possibility of using modern combined drugs of this group during pregnancy. Relieving heartburn in pregnant women through the use of non-absorbable combined antacids is supported by the FDA, the European guidelines for the treatment of GERD. The article lists antacid drugs registered in the pharmaceutical market, special attention is paid to drugs approved for use during pregnancy.

https://doi.org/10.33149/vkp.2020.02.10
PDF (Русский)
PDF (Українська)

References

1. Бурков С. Г. Гастроэзофагеальная рефлюксная болезнь у женщин в период беременности. Гинекология. 2001. Vol. 6, No 5. P. 12–15.
2. Елохина Т. Б., Тютюнник В. Л., Гастроэзофагеальная рефлюксная болезнь при беременности. Лечащий врач. 2009. № 4. С. 1–4.
3. Ивашкин В. Т. Антациды: монотерапия или компонент противоязвенного лечения в клинике внутренних болезней. Сборник “Новые эффективные лекарственные средства”. 1997. № 1. С. 31.
4. Маркетинговое агентство DSM Group. URL: http://www.dsm.ru/marketing/free-information/
5. Моисеев С. В. Алюминийсодержащие препараты: риск превышает пользу. Consilium medicum. 2006. № 6. С. 8–12.
6. Плотникова Е. Ю. Актуальность антацидов и альгинатов в лечении заболеваний органов пищеварения. Лечащий врач. 2015. № 2. С. 58–63.
7. Плотникова Е. Ю. Гастроэзофагеальная рефлюксная болезнь и беременность. Современный журнал практического врача iDOKTOR. 2015. № 1(30). С. 29–32.
8. Соколова В. И., Горелова С. В. Анализ аптечных продаж противоязвенных препаратов и антацидов в РФ за 2001–2002 гг. Ремедиум. 2003. № 5. С. 27–34.
9. Ушкалова Е. А. Клиническая фармакология современных антацидов. Фарматека. 2006. № 11. С. 1–6.
10. Фадеенко Г. Д. Роль и место антацидов в лечении кислотозависимых заболеваний. Здоровье Украины. 2007. № 20/1. С. 30–32.
11. Шептулин А. А. Новое в антацидной терапии кислотозависимых заболеваний. Рос. журн. гастроэнтерол., гепатол., колопроктол. 1997. № 3. С. 53–55.
12. Шилова С. Д. Анализ аптечных продаж противоязвенных препаратов и антацидов в РФ за 2000–2001 гг. Российские аптеки. 2002. № 4. С. 5–9.
13. Arnold R., Koop H., Schwarting H., Tuch K., Willemer B. Effect of acid inhibition on gastric endocrine cells. Scand. J. Gastroenterol. 1986. Vol. 21, No 125. P. 14–19.
14. Briggs G. G., Freeman R. Y., Yaffe S. J. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Baltimore, USA: William and Wilkins, 2002.
15. Demling L. The conservative therapy of gastritis and peptic ulcer. Internist (Berl). 1963. P. 193–196.
16. Hollander D., Harlan J. Antacids vs placebos in peptic ulcer therapy. A controlled doubleblind investigation. JAMA. 1973. Vol. 226. P. 1181–1185.
17. Hollander D., Tarnawski A., Gergely H. Protection against alcohol-induced gastric mucosal injury by aluminium-containing compounds-sucralfate, antacids, and aluminium sulfate. Scand. J. Gastroenterol. 1986. Vol. 1, No 125. P. 151–153.
18. Konturek S. J., Bilski S., Kwiecien N., Obtulowicz W., Kopp B,. Oleksy J. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism. Gut. 1987. Vol. 28. P. 1557–1563.
19. Lacroix I., Damase-Michel C., Lapeyre-Mestre M., Montastruc J. L. Prescription of drugs during pregnancy in France. Lancet. 2000. Vol. 356, No 18. P. 1735–1736.
20. McGuinness B., Logan J. I. Milk alkali syndrome. Ulster Med. J. 2002. Vol. 71, No 2. P. 132–135.
21. Murray J. R. Antacids for duodenal ulcer. Br. Med. J. (Clin. Res. Ed). 1981. Vol. 283, No 6283. P. 61.
22. Piper D. W. Antacid and anticholinergic drug therapy of peptic ulcer. Gastroenterology. 1967. Vol. 52, No 6. P. 1009–1018.
23. Piper D. W., Barbara H. F. Antacid therapy of peptic ulcer. Gut. 1964. Vol. 5, No 6. P. 585–589.
24. Piper D. W., Baume P. E., Stiel J. N. The medical treatment of chronic peptic ulcer. Med. J. Aust. 1967. Vol. 1, No 21. P. 1071–1075.
25. Priebe J. H., Skillman J. J., Bushnell L. S., Long P. C., Silen W. Antacid versus cimetidine in preventing acute gastrointestinal bleeding: a randomised trial in 75 critically ill patients. N. Engl. J. Med. 1980. Vol. 302. P. 426–430.
26. Richter J. E., Kahrilas P. J., Johanson J. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol. 2001. Vol. 96. P. 656–665.
27. Tarnawski A., Hollander D., Cummings D., Krause W. J., Gergely H., Zipser R. D. Are antacids acid neutralisers only? Histologic, ultrastructural and functional changes in normal gastric mucosa induced by antacids. Gastroenterology. 1984. Vol. 86. P. 1276.
28. Tarnawski A., Hollander D., Gergely H., Stachura J. Comparison of antacid, sucralfate, cimetidine and ranitidine in protection of the gastric mucosa against ethanol injury. Am. J. Med. 1985. Vol. 79. P. 19–23.
29. Vedavathi H., et al. Evaluation of cost effectiveness and efficacy of commonly used different antacid gel preparations. Int. J. Basic Clin. Pharmacol. 2013. Vol. 2, No 6. P. 788–791.